NCT00231777

A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)

A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety and Tolerability of IV MK0517 for the Prevention of Postoperative Nausea and Vomiting (PONV)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 216 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is already available to patients for this indication.

Conditions

• Post-Operative Nausea and Vomiting

Interventions

Type	Name	Description
DRUG	Comparator: MK0517	a single administration of 40 mg MK0517 by IV immediately prior to surgery
DRUG	Comparator: ondansetron	a single administration of 4 mg ondansetron by IV immediately prior to surgery

Timeline

• Start date: 2005-07-01
• Primary completion: 2005-11-01
• Completion: 2005-11-01
• First posted: 2005-10-04
• Last updated: 2015-08-19
• Results posted: 2010-06-08